A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM

NCT03560973 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

164

Enrollment

OTHER

Sponsor class

Conditions

Mesothelioma

Interventions

DRUG: Gemcitabine
DRUG: Ramucirumab

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica